new Delhi: Prime Minister Narendra Modi held a meeting on the current status and future prospects of the corona vaccine strategy in India. During this time, PM Modi discussed all the aspects related to the vaccine.
PM Modi tweeted, “Review meeting on India’s vaccination strategy and future prospects. Important issues related to the progress of vaccine development, regulatory approvals and procurement were discussed. “
Held a meeting to review India’s vaccination strategy and the way forward. Important issues related to progress of vaccine development, regulatory approvals and procurement were discussed. pic.twitter.com/nwZuoMFA0N
– Narendra Modi (@narendramodi) November 20, 2020
PM Modi said, “reviewed various issues like adding vaccine and technology platforms for vaccination roll-out, accessing HCWs, priority of population groups for cold-chain infrastructure growth.”
Haryana Health Minister gets Covaxin vaccine first
Let us know that the Haryana Home Minister and Health Minister Anil Vij has got himself vaccinated as a volunteer in the cocaine test. The trial of the third phase of the drug, Bharat Biotech and the Indian Council of Medical Research Council Kovaxin has started from today to protect the corona virus epidemic in the state. Health Minister Anil Vij had already announced that he would first get himself vaccinated under the supervision of doctors as a volunteer in the covicin test.
Phase I and Phase II vaccine trials successful
Explain that the first phase and second phase of vaccine testing and analysis has been successful and now the third phase of testing is being started. In the first and second phase of human trials, about one thousand volunteers were given this vaccine. The third phase of this vaccine is being tested in 25 centers in India with 26,000 people. This is the largest human clinical trial conducted for the Kovid-19 vaccine in India.
Volunteers will be given two intramuscular injections within approximately 28 days during the test. The test has been double blinded so that the investigator, participants and the company will not know to which group they are assigned. In this, volunteers will be given covaxine or placebo. Volunteers willing to participate in this test must be over 18 years of age. This multicenter third face trial will take place in 22 locations in India.